The identification of miR-gene pathway regulating the sensitivity of platinum agentsfor gastric cancer and its clinical applicatio

顺铂联合S-1是治疗不能切除或复发的胃癌的标准方案。然而，在接受以顺铂为基础的方案的患者中，经常观察到3/4级不良事件。奥沙利铂(L-OHP)是第三代铂类化合物，基于L-OHP的顺铂方案在食道癌的III期大型研究中显示出与顺铂方案的非劣性。此外，L-OHP毒性小、耐受性好，特别是在老年患者中，与顺铂相比有显著的生存优势。在本研究中，我们检测了调控铂类药物敏感性的新基因在临床样本中的表达，以及这些基因的表达是否与临床样本对顺铂的敏感性有关。

A platinum agent, cisplatin (CDDP) plus S-1 is the standard regimenfor unresectable or recurrent gastric cancer. However, grade 3/4 adverse events arefrequently observed in patients received with CDDP based regimen. Oxaliplatin (L-OHP)is a third-generation platinum compound and the non-inferiority of L-OHP-based regimensto CDDP-based regimen was demonstrated in large phase III study for esophagogastric cancer.Furthermore, L-OHP is associated with less toxicity and better tolerability, especiallyin older patients and significant survival benefit over CDDP. In the current study, weexamined the expression of the novel genes regulating the sensitivity for platinum agentsin clinical samples and whether these genes expression is associated with the sensitivityto CDDP using by clinical samples.